LAVAL, QC, Sept. 9, 2022 /PRNewswire/ — Bausch Wellness Organizations Inc. (NYSE/TSX: BHC) (“the Business”), and its gastroenterology company Salix Prescribed drugs, right now responded to the U.S. Foodstuff and Drug Administration’s (Food and drug administration) tentative approval of the Norwich Prescription drugs rifaximin 200 mg merchandise. The Corporation understands this was a Paragraph III submitting. A Paragraph III submitting is made when an Abbreviated New Drug Application (ANDA) applicant does not intend to marketplace its generic item until the patent expiration. The Fda will thus not grant full acceptance right until the expiry of the previous of the Company’s Orange Guide stated patents for the XIFAXAN® (rifaximin) 200 mg…